Literature DB >> 21317914

A good molecular target for prostate cancer chemotherapy.

Sidney R Grimes1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21317914      PMCID： PMC3739207          DOI： 10.1038/aja.2010.172

Source DB:  PubMed          Journal:  Asian J Androl        ISSN： 1008-682X            Impact factor:   3.285


× No keyword cloud information.
  19 in total

1.  Interaction of the mitotic kinesin Eg5 inhibitor monastrol with P-glycoprotein.

Authors:  Tanja Peters; Heike Lindenmaier; Walter E Haefeli; Johanna Weiss
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-12-20       Impact factor: 3.000

2.  Systemic chemotherapy and new experimental approaches in the treatment of metastatic prostate cancer.

Authors:  C N Sternberg
Journal:  Ann Oncol       Date:  2008-09       Impact factor: 32.976

3.  Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients.

Authors:  Simona Mozzetti; Cristiano Ferlini; Paola Concolino; Flavia Filippetti; Giuseppina Raspaglio; Silvia Prislei; Daniela Gallo; Enrica Martinelli; Franco Oreste Ranelletti; Gabriella Ferrandina; Giovanni Scambia
Journal:  Clin Cancer Res       Date:  2005-01-01       Impact factor: 12.531

4.  Docetaxel-resistant prostate cancer cells remain sensitive to S-trityl-L-cysteine-mediated Eg5 inhibition.

Authors:  Carolyn Wiltshire; Babloo L Singh; Jacqueline Stockley; Janis Fleming; Brendan Doyle; Robert Barnetson; Craig N Robson; Frank Kozielski; Hing Y Leung
Journal:  Mol Cancer Ther       Date:  2010-06-01       Impact factor: 6.261

5.  A potent chemotherapeutic strategy for bladder cancer: (S)-methoxy-trityl-L-cystein, a novel Eg5 inhibitor.

Authors:  Sentai Ding; Koji Nishizawa; Takashi Kobayashi; Shinya Oishi; Jiajv Lv; Nobutaka Fujii; Osamu Ogawa; Hiroyuki Nishiyama
Journal:  J Urol       Date:  2010-07-21       Impact factor: 7.450

Review 6.  Beyond taxanes: a review of novel agents that target mitotic tubulin and microtubules, kinases, and kinesins.

Authors:  Michael R Harrison; Kyle D Holen; Glenn Liu
Journal:  Clin Adv Hematol Oncol       Date:  2009-01

7.  Corticosteroid co-medication does not reduce the incidence and severity of neurotoxicity induced by docetaxel.

Authors:  L C Pronk; P H Hilkens; M J van den Bent; W L van Putten; G Stoter; J Verweij
Journal:  Anticancer Drugs       Date:  1998-10       Impact factor: 2.248

8.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

9.  Effects of Eg5 knockdown on human prostate cancer xenograft growth and chemosensitivity.

Authors:  Norihiro Hayashi; Erich Koller; Ladan Fazli; Martin E Gleave
Journal:  Prostate       Date:  2008-09-01       Impact factor: 4.104

10.  Synthesis and biological evaluation of L-cysteine derivatives as mitotic kinesin Eg5 inhibitors.

Authors:  Naohisa Ogo; Shinya Oishi; Kenji Matsuno; Jun-ichi Sawada; Nobutaka Fujii; Akira Asai
Journal:  Bioorg Med Chem Lett       Date:  2007-05-03       Impact factor: 2.823
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.